Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus – A MASTERMIND precision medicine approach (UKPDS 87)

Autor: Andrew T. Hattersley, Rury R. Holman, Ewan R. Pearson, Angus G. Jones, Beverley M. Shields, Ruth L. Coleman, Olorunsola F. Agbaje
Rok vydání: 2020
Předmět:
Blood Glucose
Male
Chlorpropamide
medicine.medical_specialty
Time Factors
endocrine system diseases
Endocrinology
Diabetes and Metabolism
medicine.medical_treatment
030209 endocrinology & metabolism
Type 2 diabetes
03 medical and health sciences
0302 clinical medicine
Endocrinology
Risk Factors
Diabetes mellitus
Internal medicine
Glyburide
Internal Medicine
medicine
Humans
Hypoglycemic Agents
Insulin
In patient
030212 general & internal medicine
Precision Medicine
Glycated Hemoglobin
Glucose lowering
Drug Substitution
business.industry
nutritional and metabolic diseases
Type 2 Diabetes Mellitus
General Medicine
Middle Aged
Prognosis
medicine.disease
Precision medicine
Metformin
United Kingdom
Treatment Outcome
Diabetes Mellitus
Type 2
Drug Therapy
Combination
Female
business
Follow-Up Studies
medicine.drug
Zdroj: Diabetes Research and Clinical Practice. 166:108333
ISSN: 0168-8227
Popis: Aims Predicting likely durability of glucose-lowering therapies for people with type 2 diabetes (T2D) could help inform individualised therapeutic choices. Methods We used data from UKPDS patients with newly-diagnosed T2D randomised to first-line glucose-lowering monotherapy with chlorpropamide–glibenclamide–basal insulin or metformin. In 2,339 participants who achieved one-year HbA1c values Results Follow-up was median (IQR) 11.0 (8.0–14.0) years. Monotherapy-failure occurred in 72%–82%–75% and 79% for those randomised to chlorpropamide–glibenclamide–basal insulin or metformin respectively–after median 4.5 (3.0–6.6)–3.7 (2.6–5.6)–4.2 (2.7–6.5) and 3.8 (2.6– 5.2) years. Time-to-monotherapy-failure was predicted primarily by HbA1c and BMI values–with other risk factors varying by type of monotherapy–with predictions to within ±2.5 years for 55%–60%–56% and 57% of the chlorpropamide–glibenclamide–basal insulin and metformin monotherapy cohorts respectively. Conclusions Post one-year glycaemic durability can be predicted robustly in individuals with newly-diagnosed T2D who achieve HbA1c values
Databáze: OpenAIRE
Externí odkaz: